Temat: "Antibodies, Viral" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Seroprevalence of SARS-CoV-2 antibodies among healthcare workers in Dutch hospitals after the 2020 first wave: a multicentre cross-sectional study with prospective follow-up.
Autorzy:: Recanatini C; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. .
GeurtsvanKessel CH; Viroscience Department, Erasmus University Medical Center, Rotterdam, The Netherlands.
Pas SD; Microvida Laboratory for Medical Microbiology, Bravis Hospital, Roosendaal, The Netherlands.; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Broens EM; Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Maas M; Department of Internal Medicine, Bernhoven Hospital, Uden, The Netherlands.
van Mansfeld R; Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Mutsaers-van Oudheusden AJG; Department of Infection Control, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
van Rijen M; Department of Infection Control, Amphia Hospital, Breda, The Netherlands.
Schippers EF; Department of Internal Medicine, Haga Hospital, The Hague, The Netherlands.
Stegeman A; Department of Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Tami A; Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Veldkamp KE; Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Visser H; Department of Internal Medicine, Beatrix Hospital, Gorinchem, The Netherlands.
Voss A; Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Wegdam-Blans MCA; Catharina Hospital, Eindhoven, The Netherlands.; Hospital St. Jans Gasthuis, Weert, The Netherlands.; Department of Medical Microbiology, Stichting PAMM, Veldhoven, The Netherlands.
Wertheim HFL; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Wever PC; Department of Medical Microbiology and Infection Control, Jeroen Bosch Hospital, 's Hertogenbosch, The Netherlands.
Koopmans MPG; Viroscience Department, Erasmus University Medical Center, Rotterdam, The Netherlands.
Kluytmans JAJW; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Infection Control, Amphia Hospital, Breda, The Netherlands.; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Kluytmans-van den Bergh MFQ; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Infection Control, Amphia Hospital, Breda, The Netherlands.; Amphia Academy Infectious Disease Foundation, Amphia Hospital, Breda, The Netherlands.; Pokaż więcej
Corporate Authors:: COCON Study Group
Źródło:: Antimicrobial resistance and infection control [Antimicrob Resist Infect Control] 2023 Nov 29; Vol. 12 (1), pp. 137. Date of Electronic Publication: 2023 Nov 29.
Typ publikacji:: Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Viral*/blood
COVID-19*/epidemiology
Humans ; Cross-Sectional Studies ; Diabetes Mellitus ; Fatigue ; Follow-Up Studies ; Health Personnel ; Hospitals ; Pain ; Prospective Studies ; Retrospective Studies ; Seroepidemiologic Studies ; Netherlands

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection.
Autorzy:: Ferrari L; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.; Department of Infectious Diseases, Fondazione PTV, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Ruggiero A; Department of Neurosciences, Biomedicine and Movement Sciences, School of Medicine, University of Verona, Verona, Italy.
Stefani C; Department of Neurosciences, Biomedicine and Movement Sciences, School of Medicine, University of Verona, Verona, Italy.
Benedetti L; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Piermatteo L; Department of Biology, University of Rome Tor Vergata, Rome, Italy.
Andreassi E; Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
Caldara F; Department of Infectious Diseases, Fondazione PTV, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Zace D; Department of Infectious Diseases, Fondazione PTV, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Pagliari M; Laboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale Delle Venezie, Legnaro, Italy.
Ceccherini-Silberstein F; Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
Jones C; Department of Primary Care and Public Health, Brighton and Sussex Medical School, Falmer, UK.
Iannetta M; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.; Department of Infectious Diseases, Fondazione PTV, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Geretti AM; Department of Infectious Diseases, Fondazione PTV, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy. anna_.; Department of Infection, North Middlesex University Hospital, London, UK. anna_.; School of Immunity & Microbial Sciences, King's College London, London, UK. anna_.; Pokaż więcej
Corporate Authors:: EVAN-COV Study Group
Źródło:: Scientific reports [Sci Rep] 2024 Apr 09; Vol. 14 (1), pp. 8337. Date of Electronic Publication: 2024 Apr 09.
Typ publikacji:: Journal Article
MeSH Terms:: HIV Infections*
COVID-19*/prevention & control
Spiders*
Adult ; Animals ; Humans ; SARS-CoV-2 ; BNT162 Vaccine ; COVID-19 Vaccines/adverse effects ; Immunoassay ; Antibodies ; Vaccination ; Antibodies, Viral ; Antibodies, Neutralizing

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population.
Autorzy:: Hernández-Bello J; Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud Universidad de Guadalajara, Guadalajara, Mexico.
Lorenzo-Leal AC; Division of Infectious Diseases, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Muñoz-Valle JF; Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud Universidad de Guadalajara, Guadalajara, Mexico.
Morales-Núñez JJ; Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud Universidad de Guadalajara, Guadalajara, Mexico.
Díaz-Pérez SA; Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud Universidad de Guadalajara, Guadalajara, Mexico.
Hernández-Gutiérrez R; Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Jalisco, Mexico.
Bach H; Division of Infectious Diseases, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Apr 04; Vol. 19 (4), pp. e0299520. Date of Electronic Publication: 2024 Apr 04 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: SARS-CoV-2*
COVID-19*/prevention & control
Humans ; Antibodies, Neutralizing ; Mexico/epidemiology ; Pandemics ; COVID-19 Vaccines ; Vaccination ; Antibodies, Viral
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Post-vaccination SARS-CoV-2 IgG spike antibody responses among clinical and non-clinical healthcare workers at a tertiary facility in Kenya.
Autorzy:: Mwangi LW; Research Division, Medical College East Africa, The Aga Khan University Hospital, Nairobi, Kenya.
Omuse G; Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Nairobi, Kenya.
Adam R; Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Nairobi, Kenya.; Department of Internal Medicine, The Aga Khan University Hospital, Nairobi, Kenya.
Ong'ete G; Occupational Safety and Health, The Aga Khan University Hospital, Nairobi, Kenya.
Matheka C; Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Nairobi, Kenya.
Mugaine P; Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Nairobi, Kenya.
Sayed S; Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Nairobi, Kenya.
Maina D; Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Nairobi, Kenya.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Apr 04; Vol. 19 (4), pp. e0299302. Date of Electronic Publication: 2024 Apr 04 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/epidemiology
COVID-19*/prevention & control
Vaccines*
Humans ; Kenya/epidemiology ; Antibody Formation ; SARS-CoV-2 ; Seroepidemiologic Studies ; Vaccination ; Antibodies, Viral ; Health Personnel ; Immunoglobulin G
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.
Autorzy:: Ezzikouri S; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco. .
Tajudeen R; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia.
Majidi H; Ministry of Health and Social Protection, Rabat, Morocco.
Redwane S; Direction Régionale de la santé Casablanca-Settat, Observatoire régional de santé, Casablanca, Morocco.
Aqillouch S; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco.
Abdulaziz M; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia.
Aragaw M; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia.
Papa Fallah M; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia.
Sembuche S; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia.
Batcho S; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia.
Kabwe P; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia.
Gonese E; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia.
Laazaazia O; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco.
Elmessaoudi-Idrissi M; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco.
Meziane N; Centre Régional de Transfusion Sanguine, Casablanca, Morocco.
Ainahi A; Hormonology and Tumor Markers Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco.
Sarih M; Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, Casablanca, Morocco.
Ogwell Ouma AE; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia.
Maaroufi A; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Apr 03; Vol. 14 (1), pp. 7817. Date of Electronic Publication: 2024 Apr 03.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19 Vaccines*
COVID-19*/epidemiology
COVID-19*/prevention & control
Female ; Humans ; ChAdOx1 nCoV-19 ; BNT162 Vaccine ; Morocco/epidemiology ; Cross-Sectional Studies ; Seroepidemiologic Studies ; SARS-CoV-2 ; Antibodies, Viral ; Immunoglobulin G ; Chronic Disease

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Determinants of health as predictors for differential antibody responses following SARS-CoV-2 primary and booster vaccination in an at-risk, longitudinal cohort.
Autorzy:: Echeverri Tribin F; Department of Biomedical Engineering, University of Miami, Miami, Florida, United States of America.; University of Miami Miller School of Medicine, Miami, Florida, United States of America.
Williams E; Department of Biomedical Engineering, University of Miami, Miami, Florida, United States of America.; Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, United States of America.
Testamarck V; Indiana University School of Medicine, Indianapolis, IN, United States of America.
Carreño JM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
Bielak D; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Yellin T; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
Hoffer M; Department of Biomedical Engineering, University of Miami, Miami, Florida, United States of America.; Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, Florida, United States of America.
Pallikkuth S; Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, United States of America.
Pahwa S; Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Apr 02; Vol. 19 (4), pp. e0292566. Date of Electronic Publication: 2024 Apr 02 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: SARS-CoV-2*
COVID-19*/prevention & control
Female ; Humans ; Antibody Formation ; 2019-nCoV Vaccine mRNA-1273 ; Cross-Sectional Studies ; Antibodies ; Vaccination ; Antibodies, Viral

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex.
Autorzy:: Du P; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
Huang L; Stemirna Therapeutics, Shanghai, China.
Fang Y; Stemirna Therapeutics, Shanghai, China.
Zhao F; Stemirna Therapeutics, Shanghai, China.
Li Q; Stemirna Therapeutics, Shanghai, China.
Ma X; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
Li R; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.; Medical School, University of Chinese Academy of Sciences, Beijing, China.
Chen Q; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.; Faculty of Health Sciences, University of Macau, Macau, China.
Shen H; Stemirna Therapeutics, Shanghai, China.
Wang Q; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.; Medical School, University of Chinese Academy of Sciences, Beijing, China.; Faculty of Health Sciences, University of Macau, Macau, China.
Li H; Stemirna Therapeutics, Shanghai, China.
Gao GF; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.; Medical School, University of Chinese Academy of Sciences, Beijing, China.; Faculty of Health Sciences, University of Macau, Macau, China.; Pokaż więcej
Źródło:: PLoS pathogens [PLoS Pathog] 2024 Apr 01; Vol. 20 (4), pp. e1012116. Date of Electronic Publication: 2024 Apr 01 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: mRNA Vaccines*
COVID-19*/prevention & control
Animals ; Humans ; Mice ; COVID-19 Vaccines ; Macaca mulatta ; Immunization, Secondary ; Mice, Transgenic ; RNA, Messenger/genetics ; SARS-CoV-2/genetics ; Antibodies, Neutralizing ; Antibodies, Viral

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Plant virus-derived nanoparticles decorated with genetically encoded SARS-CoV-2 nanobodies display enhanced neutralizing activity.
Autorzy:: Merwaiss F; Instituto de Biología Molecular y Celular de Plantas, Consejo Superior de Investigaciones Científicas - Universitat Politècnica de València, Valencia, Spain.
Lozano-Sanchez E; Instituto de Biología Molecular y Celular de Plantas, Consejo Superior de Investigaciones Científicas - Universitat Politècnica de València, Valencia, Spain.
Zulaica J; Institute for Integrative Systems Biology, Consejo Superior de Investigaciones Científicas - Universitat de València, Paterna, Spain.
Rusu L; Institute for Integrative Systems Biology, Consejo Superior de Investigaciones Científicas - Universitat de València, Paterna, Spain.
Vazquez-Vilar M; Instituto de Biología Molecular y Celular de Plantas, Consejo Superior de Investigaciones Científicas - Universitat Politècnica de València, Valencia, Spain.
Orzáez D; Instituto de Biología Molecular y Celular de Plantas, Consejo Superior de Investigaciones Científicas - Universitat Politècnica de València, Valencia, Spain.
Rodrigo G; Institute for Integrative Systems Biology, Consejo Superior de Investigaciones Científicas - Universitat de València, Paterna, Spain.
Geller R; Institute for Integrative Systems Biology, Consejo Superior de Investigaciones Científicas - Universitat de València, Paterna, Spain.
Daròs JA; Instituto de Biología Molecular y Celular de Plantas, Consejo Superior de Investigaciones Científicas - Universitat Politècnica de València, Valencia, Spain.; Pokaż więcej
Źródło:: Plant biotechnology journal [Plant Biotechnol J] 2024 Apr; Vol. 22 (4), pp. 876-891. Date of Electronic Publication: 2023 Nov 15.
Typ publikacji:: Journal Article
MeSH Terms:: Single-Domain Antibodies*/genetics
COVID-19*/genetics
Plant Viruses*
Nanoparticles*/chemistry
Spike Glycoprotein, Coronavirus*
Humans ; SARS-CoV-2/genetics ; SARS-CoV-2/metabolism ; Antibodies, Neutralizing ; Antibodies, Viral

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses.
Autorzy:: Matsuura T; Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahi-Machi, Abeno-ku, Osaka, 545-8585, Japan. .; Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. .
Fukushima W; Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahi-Machi, Abeno-ku, Osaka, 545-8585, Japan.; Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.; Osaka International Research Center for Infectious Diseases, Osaka, Japan.
Nakagama Y; Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.; Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Kido Y; Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.; Osaka International Research Center for Infectious Diseases, Osaka, Japan.; Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Kase T; Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahi-Machi, Abeno-ku, Osaka, 545-8585, Japan.; Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Kondo K; Management Bureau, Osaka Metropolitan University Hospital, Osaka, Japan.
Kaku N; Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.; Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Matsumoto K; Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahi-Machi, Abeno-ku, Osaka, 545-8585, Japan.
Suita A; Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahi-Machi, Abeno-ku, Osaka, 545-8585, Japan.
Mukai E; Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahi-Machi, Abeno-ku, Osaka, 545-8585, Japan.
Nitahara Y; Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Konishi A; Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahi-Machi, Abeno-ku, Osaka, 545-8585, Japan.
Kasamatsu A; Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahi-Machi, Abeno-ku, Osaka, 545-8585, Japan.
Nakagama S; Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Nakagami-Yamaguchi E; Department of Medical Quality and Safety Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Ohfuji S; Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahi-Machi, Abeno-ku, Osaka, 545-8585, Japan.; Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Kaneko Y; Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.; Osaka International Research Center for Infectious Diseases, Osaka, Japan.; Department of Bacteriology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Kaneko A; Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.; Osaka International Research Center for Infectious Diseases, Osaka, Japan.; Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Kakeya H; Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.; Osaka International Research Center for Infectious Diseases, Osaka, Japan.; Department of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Hirota Y; Clinical Epidemiology Research Center, SOUSEIKAI Medical Group (Medical Co. LTA), Fukuoka, Japan.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Mar 27; Vol. 14 (1), pp. 7217. Date of Electronic Publication: 2024 Mar 27.
Typ publikacji:: Journal Article
MeSH Terms:: 2019-nCoV Vaccine mRNA-1273*
COVID-19*/prevention & control
Adult ; Male ; Humans ; SARS-CoV-2 ; BNT162 Vaccine ; COVID-19 Vaccines ; Prospective Studies ; Antibodies ; Fever ; RNA, Messenger ; Antibodies, Viral ; Vaccination

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Autorzy:: Cheng SMS; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Mok CKP; The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China.; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.; SH Ho Research Centre for Emerging Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Li JKC; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Chan KKP; Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Luk KS; Princess Margaret Hospital, Hospital Authority, Hong Kong SAR, China.
Lee BHW; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Gu H; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Chan KCK; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Tsang LCH; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Yiu KYS; Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Ling KKC; Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Tang YS; The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China.; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Luk LLH; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Yu JKM; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Pekosz A; W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Webby RJ; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Cowling BJ; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Hui DSC; Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.; SH Ho Research Centre for Emerging Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Peiris M; School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. .; Centre for Immunology and Infection, Hong Kong Science Park, Hong Kong SAR, China. .; Pokaż więcej
Źródło:: Virology journal [Virol J] 2024 Mar 21; Vol. 21 (1), pp. 70. Date of Electronic Publication: 2024 Mar 21.
Typ publikacji:: Journal Article
MeSH Terms:: BNT162 Vaccine*
COVID-19*/prevention & control
Humans ; Broadly Neutralizing Antibodies ; SARS-CoV-2/genetics ; COVID-19 Vaccines ; Antibodies, Neutralizing ; Vaccination ; Antibodies, Viral

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.
Autorzy:: Sohail MS; Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China.
Ahmed SF; Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia.; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Quadeer AA; Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia.
McKay MR; Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia.; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.; Pokaż więcej
Źródło:: Viruses [Viruses] 2024 Mar 20; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 20.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/prevention & control
Vaccines*
Humans ; COVID-19 Vaccines ; Epitopes, T-Lymphocyte/genetics ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus/genetics ; T-Lymphocytes ; Antibodies, Neutralizing ; Antibodies, Viral
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers.
Autorzy:: Gardner BJ; Department of Ecology and Evolutionary Biology, University of California, Santa Cruz, CA 95060, USA.
Kilpatrick AM; Department of Ecology and Evolutionary Biology, University of California, Santa Cruz, CA 95060, USA.; Pokaż więcej
Źródło:: Viruses [Viruses] 2024 Mar 20; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 20.
Typ publikacji:: Journal Article
MeSH Terms:: SARS-CoV-2*/genetics
COVID-19*/prevention & control
Humans ; Vaccine Efficacy ; BNT162 Vaccine ; Hospitalization ; Antibodies, Neutralizing ; Antibodies, Viral
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: SARS-CoV-2-Specific Immune Responses in Vaccination and Infection during the Pandemic in 2020-2022.
Autorzy:: Inoue W; Department of Medical Technology, School of Health Sciences and Graduate School of Medical Technology, Tokyo University of Technology, Tokyo 144-8535, Japan.
Kimura Y; Department of Medical Technology, School of Health Sciences and Graduate School of Medical Technology, Tokyo University of Technology, Tokyo 144-8535, Japan.
Okamoto S; Department of Medical Technology, School of Health Sciences and Graduate School of Medical Technology, Tokyo University of Technology, Tokyo 144-8535, Japan.
Nogimori T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan.
Sakaguchi-Mikami A; Department of Medical Technology, School of Health Sciences and Graduate School of Medical Technology, Tokyo University of Technology, Tokyo 144-8535, Japan.
Yamamoto T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan.; Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.; Department of Virology and Immunology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
Tsunetsugu-Yokota Y; Department of Medical Technology, School of Health Sciences and Graduate School of Medical Technology, Tokyo University of Technology, Tokyo 144-8535, Japan.; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan.; Research Institute, The World New Prosperity (WNP), Tokyo 169-0075, Japan.; Pokaż więcej
Źródło:: Viruses [Viruses] 2024 Mar 13; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 13.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/prevention & control
Blood Group Antigens*
Vaccines*
Humans ; SARS-CoV-2 ; Pandemics ; Vaccination ; Immunoglobulin G ; Immunity, Mucosal ; Immunoglobulin A ; Antibodies, Viral
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Viral Epitope Scanning Reveals Correlation between Seasonal HCoVs and SARS-CoV-2 Antibody Responses among Cancer and Non-Cancer Patients.
Autorzy:: Lidenge SJ; Department of Clinical Research, Training, and Consultancy, Ocean Road Cancer Institute, Dar es Salaam P.O. Box 3592, Tanzania.; Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam P.O. Box 65001, Tanzania.
Yalcin D; Department of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Bennett SJ; Department of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.; School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68516, USA.
Ngalamika O; Dermatology and Venereology Division, University Teaching Hospital, University of Zambia School of Medicine, Lusaka P.O. Box 50001, Zambia.
Kweyamba BB; Department of Clinical Research, Training, and Consultancy, Ocean Road Cancer Institute, Dar es Salaam P.O. Box 3592, Tanzania.
Mwita CJ; Department of Clinical Research, Training, and Consultancy, Ocean Road Cancer Institute, Dar es Salaam P.O. Box 3592, Tanzania.
Tso FY; Department of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Mwaiselage J; Department of Clinical Research, Training, and Consultancy, Ocean Road Cancer Institute, Dar es Salaam P.O. Box 3592, Tanzania.; Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam P.O. Box 65001, Tanzania.
West JT; Department of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Wood C; Department of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.; School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68516, USA.; Pokaż więcej
Źródło:: Viruses [Viruses] 2024 Mar 13; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 13.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*
Neoplasms*
Sarcoma, Kaposi*
Humans ; SARS-CoV-2 ; Antibody Formation ; COVID-19 Testing ; Seasons ; Antibodies, Viral ; Epitopes ; Spike Glycoprotein, Coronavirus

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: SARS-CoV-2 Antibodies in Breastmilk Three and Six Months Postpartum in Relation to the Trimester of Maternal SARS-CoV-2 Infection-An Exploratory Study.
Autorzy:: Fich L; Department of Obstetrics and Gynecology, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.
Christiansen AH; Department of Obstetrics and Gynecology, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.
Nilsson AC; Department of Clinical Immunology, Odense University Hospital, 5000 Odense, Denmark.
Lindman J; Department of Obstetrics and Gynecology, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.
Juul-Larsen HG; Department of Clinical Research, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.
Hansen CB; Department of Obstetrics and Gynecology, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.
la Cour Freiesleben N; Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark.
Khalil MR; Department of Obstetrics and Gynecology, Lillebaelt Hospital, 6000 Kolding, Denmark.
Nielsen HS; Department of Obstetrics and Gynecology, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 13; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 13.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*
Infant, Newborn ; Pregnancy ; Humans ; Female ; Child ; Male ; SARS-CoV-2 ; Milk, Human ; Prospective Studies ; Postpartum Period ; Antibodies, Viral ; Immunoglobulin G ; Mothers ; Immunoglobulin A

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.
Autorzy:: Clever S; Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Limpinsel L; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Meyer Zu Natrup C; Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Schünemann LM; Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Beythien G; Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Rosiak M; Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Hülskötter K; Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Gregor KM; Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Tuchel T; Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Kalodimou G; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Freudenstein A; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Kumar S; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Baumgärtner W; Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Sutter G; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Tscherne A; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Volz A; Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.; Pokaż więcej
Źródło:: Viruses [Viruses] 2024 Mar 08; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:: Journal Article
MeSH Terms:: SARS-CoV-2*/genetics
COVID-19*/prevention & control
gamma-Globulins*
Melphalan*
Viral Vaccines*
Vaccines, DNA*
Animals ; Humans ; Mice ; COVID-19 Vaccines ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus/genetics ; Vaccination ; Antibodies, Neutralizing

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality.
Autorzy:: Lobaina Y; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; R&D Department, Yongzhou Zhong Gu Biotechnology Co., Ltd., Yangjiaqiao Street, Lengshuitan District, Yongzhou 425000, China.
Chen R; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.
Suzarte E; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Ai P; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.
Huerta V; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Musacchio A; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Silva R; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; BCF: R&D Section, Representative Office BCF in China, Jingtai Tower, No. 24 Jianguomen Wai Street, Chaoyang District, Beijing 100022, China.
Tan C; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.
Martín A; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Lazo L; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Guillén-Nieto G; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Yang K; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.
Perera Y; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; R&D Department, Yongzhou Zhong Gu Biotechnology Co., Ltd., Yangjiaqiao Street, Lengshuitan District, Yongzhou 425000, China.; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Hermida L; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.; BCF: R&D Section, Representative Office BCF in China, Jingtai Tower, No. 24 Jianguomen Wai Street, Chaoyang District, Beijing 100022, China.; Pokaż więcej
Źródło:: Viruses [Viruses] 2024 Mar 08; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/prevention & control
Vaccines*
Animals ; Mice ; Humans ; Administration, Intranasal ; Nucleocapsid Proteins ; Vaccines, Combined ; SARS-CoV-2/genetics ; COVID-19 Vaccines ; Immunity, Mucosal ; Adjuvants, Immunologic ; Antibodies, Viral ; Antibodies, Neutralizing
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination.
Autorzy:: Martín Pérez C; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
Aguilar R; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
Jiménez A; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.; CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, 08036, Spain.
Salmerón G; Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
Canyelles M; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
Rubio R; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
Vidal M; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
Cuamba I; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.; Centro de Investigação Em Saúde de Manhiça, Maputo, CP, 1929, Mozambique.
Barrios D; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
Díaz N; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
Santano R; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.; CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, 08036, Spain.
Serra P; Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, 08036, Spain.
Santamaria P; Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, 08036, Spain.; Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 1N4, Canada.
Izquierdo L; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.; CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, 08036, Spain.
Trilla A; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.; Department of Preventive Medicine and Epidemiology, Hospital Clinic, Universitat de Barcelona, Barcelona, 08036, Spain.
Vilella A; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.; Department of Preventive Medicine and Epidemiology, Hospital Clinic, Universitat de Barcelona, Barcelona, 08036, Spain.
Barroso S; Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
Tortajada M; Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
García-Basteiro AL; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.; Centro de Investigação Em Saúde de Manhiça, Maputo, CP, 1929, Mozambique.; CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, 08036, Spain.; International Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain.
Moncunill G; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain. .; CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, 08036, Spain. .
Dobaño C; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain. .; CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, 08036, Spain. .; Pokaż więcej
Źródło:: BMC medicine [BMC Med] 2024 Mar 08; Vol. 22 (1), pp. 103. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/prevention & control
Humans ; 2019-nCoV Vaccine mRNA-1273 ; SARS-CoV-2 ; BNT162 Vaccine ; Breakthrough Infections ; Vaccination ; Immunoglobulin A ; Immunoglobulin G ; Antibodies, Viral
SCR Disease Name:: COVID-19 breakthrough infections

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Influence of nutritional supplements on antibody levels in pregnant women vaccinated with inactivated SARS-CoV-2 vaccines.
Autorzy:: Zhang X; Department of Occupational and Environmental Health, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.
Han X; Department of Occupational and Environmental Health, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.
Chen B; Department of Occupational and Environmental Health, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.
Fu X; Department of Occupational and Environmental Health, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.
Gong Y; Department of Epidemiology and Medical Statistics, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.
Yang W; Department of Child and Adolescent Health, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.
Chen Q; Department of Occupational and Environmental Health, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Mar 07; Vol. 19 (3), pp. e0289255. Date of Electronic Publication: 2024 Mar 07 (Print Publication: 2024).
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: COVID-19*/prevention & control
COVID-19 Vaccines*
Female ; Humans ; Pregnancy ; Antibodies, Neutralizing ; Antibodies, Viral ; Cross-Sectional Studies ; Dietary Supplements ; Folic Acid ; Immunoglobulin G ; Iron ; Pregnant Women ; SARS-CoV-2 ; Vaccines, Inactivated ; Adolescent ; Young Adult ; Adult ; Middle Aged

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins.
Autorzy:: Kumar S; Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.
Dasgupta S; Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.
Sajadi MM; Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.; Division of Clinical Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.; Department of Medicine, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.
Snyder GA; Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.; Department of Medicine, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.
DeVico AL; Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.; Department of Medicine, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.
Ray K; Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.; Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.; Pokaż więcej
Źródło:: Viruses [Viruses] 2024 Mar 06; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*
HIV-1*
Humans ; Spike Glycoprotein, Coronavirus ; SARS-CoV-2 ; Pandemics ; Antibodies, Neutralizing ; HIV Antibodies/analysis ; Antibodies, Monoclonal ; Virion/metabolism ; Antibodies, Viral/chemistry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Antibodies, Viral"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język